NewslettersPancreatic Cell NewsAn EGFR/HER2-Targeted Conjugate Sensitizes Gemcitabine-Sensitive and Resistant Pancreatic Cancer through Different SMAD4-Mediated MechanismsBy Bob - September 27, 2022098To overcome chemoresistance in PDAC, researchers aimed to study dual-targeting ligand-based lidamycin efficacy when combined with gemcitabine and exploreed its mechanisms of action.[Nature Communications]Full Article